Category: Partners

SHELTON, CONNECTICUT / ACCESS Newswire / September 9, 2025 / NanoViricides, Inc. (NYSE American:NNVC ) (the “Company”), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be presenting on Wednesday, September 17th, at 12:30pm at the Life Science Executive Partnering (“LSX”) World Congress 2025 in Boston, MA.

Event Information:

Event	NanoViricides Presentation at the LSX World Congress, 2025, Boston, MA
Day & Date	Wednesday, September 17, 2025
Time	12:30 pm
Location	LSX Biotech ShowCase (Day 2), Thomas Michael Menino (Boston) Convention and Exhibition Center, Boston, MA.

Anil R. Diwan, PhD, President and Executive Chairman of the Company will provide an update on the Company, its Drug Pipeline and Platform Technologies available for licensing.

Dr. Diwan has several pre-scheduled meetings in the partnering sessions and will also be available for meetings during the Congress on September 16th and 17th outside his busy schedule.

NanoViricides’ Current Antiviral Drugs Pipeline

The nanoviricides™ platform technology is yielding novel antiviral drug candidates against a number of challenging viral targets at a rapid pace.

Our most advanced candidate, NV-387, is an ultra-broad-spectrum antiviral with potential activity against most respiratory human pathogenic viruses – and more, because it emulates the attachment receptor family of sulfated proteoglycans that over 90% of human viruses utilize.

Moreover, NV-387 is designed to shape-shift upon binding to the virus particle, in the process disrupting the virus particle and making it incapable of infection, as a complete chemical nanomachine that destroys the virus.

The revolutionary broad antiviral spectrum of NV-387 is reminiscent of the dawn of antibiotics to combat bacterial infections.

Viruses are unlikely to escape NV-387 because no matter how much a virus evolves, it continues to utilize and require binding to sulfated proteoglycans – the very characteristic that NV-387 emulates. This solves the long-standing problem of antiviral medicines, that viruses escape them. Vaccines, antibodies and small chemical drugs are readily escaped by viruses as the viruses evolve in the field. This has been repeatedly observed during the recent COVID-19 pandemic, as well as in the course of most of the other viral epidemics including Influenza and HIV/AIDS.

Continued redevelopment or “updating” of vaccines necessitated by the viral escape or drift has recurrently cost billions of dollars every year for Influenza as well as COVID. NV-387 promises to make such costly endeavors unnecessary, once this drug is approved by regulatory bodies.

NV-387 is rapidly moving towards Phase II Safety, Tolerability and Efficacy Evaluation for the Treatment of MPOX disease, in response to the continuing Public Health Emergency of International Concern in WHO African Region. We already have received preliminary approval of the clinical protocol and the study and now we are working diligently to finish and submit the clinical trial application.

NV-387 was found to be highly effective against the “tripledemic” respiratory viruses, namely RSV, Influenza A, and Coronaviruses, in respective lethal animal models of lung infection. NV-387 was found to be substantially superior to existing drugs, and even resulted in complete cure in the RSV animal study.

Further, NV-387 has shown excellent effectiveness in lethal lung infection animal models relevant for Smallpox and MPox viruses.

Additionally, NV-387 has shown excellent effectiveness in lethal lung infection in a humanized (hCD150+ knock-in) mouse model by the Measles virus. Cases of Measles have been rapidly rising in the developing world including USA, Canada, UK and European countries. Measles is an important health threat because the disease can lead to “immune amnesia”, wiping out pre-developed immunity against other diseases, because it attacks the immune system itself.

At present, there are no generally approved drugs for the treatment of RSV, MPox, or Measles. The latter two are orphan diseases in the USA and will be eligible for earning a “Priority Review Voucher” (PRV) from the US FDA plus several years of market exclusivity upon approval. Each PRV is currently thought to be worth $150 million to $350 million as a tradable asset.

Additionally, NV-387’s success in treating MPox is expected to make it feasible to achieve US FDA regulatory approval as a Smallpox therapeutic, a much-needed drug for the US Bioterrorism defense strategy, with potential lucrative US Government and International contracts for stockpiling in the range of several hundred millions of dollars, assuming NV-387 is successful in a Phase II clinical trial for MPox treatment.

The overall market size of NV-387 indications is estimated to be well in excess of $10 billion.

NV-387 is expected to become an “emperic therapy” for viral infections, just as antibiotics such as amoxicillin are used as emperic therapies for bacterial infections.

NV-387 would be the first ever drug enabling emperic antiviral therapy, and would be potentially as revolutionary to antiviral therapy as antibiotics have been to anti-bacterial therapy. Emperic therapy means when the patient presents to the doctor, immediately the antiviral drug can be prescribed and started without having to wait for discriminating test results as to which virus is causing the infection. This has tremendous benefits since antiviral drugs are most effective when given as early as possible upon viral infection.

In addition, the Company has developed a clinical-ready pan-herpesvirus drug candidate, NV-HHV-1 that has shown activity against HSV-1, HSV-2 and VZV, and is expected to have activity against CMV, HHV-6, and HHV-8 as well.

The Company has also developed an anti-HIV drug candidate, NV-HIV-1, that has shown strong efficacy in SCID-hu-Thy-Liv animal model of HIV infection. NV-HHV-1 mimics the landing site on cellular CD4 that is required for all HIV viruses to cause cellular infection. Thus, HIV, despite constant changes, will be unable to escape NV-HHV-1.

NanoViricide Platform Enables Drug Rescue, Oral Drug Delivery, and Zip-Code Specific Delivery

Oral drug delivery of small chemicals, peptides (such as the GLP-a obesity drugs), and proteins is feasible by encapsulation of the guest drug into the nanoviricide polymeric micelle. The encapsulation protects the guest from metabolism thereby enabling effective drug delivery.

Encapsulation of a difficult or failed drug within the nanoviricide polymeric micelle can enable rescue of the drug candidate turning it into a clinically viable drug candidate, saving hundreds of millions of dollars of development work.

Going another step further, the nanoviricide platform technology can be customized to enable zip-code-like specific delivery of encapsulated drugs to specific tissues (e.g. non-liver targeted delivery),, cells (e.g. cancer-cell specific delivery sparing normal cells), bacteria, or viruses (e.g. NV-HHV-1, NV-HIV-1) in a fully synthetic chemistry based, scalable technology stack.

ABOUT LSX WORLD CONGRESS

Life Science Executive Partnering (LSX) World Congress will be held on Sept 16-17, with Forums on Sept 15, 2025, at the Thomas Michael Menino Convention & Exhibition Center, Boston, USA.

What is LSX World Congress-USA ? LSX World Congress-USA is where innovators, investors and senior life science dealmakers in the LSX community connect, learn and partner. The Congress gathers leaders from the US biotech, medtech, and pharmatech sectors to network, showcase innovations, and explore partnership opportunities. It offers a unique platform for CEOs, investors, and pharma executives to engage in meaningful discussions and collaborative sessions, shaping the future of healthcare technology. Empowering innovation, accelerating investment and facilitating partnering to shape the future of healthcare is the objective of LSX World Congress.

ABOUT NANOVIRICIDES

NanoViricides, Inc. (the “Company”) (www.nanoviricides.com) is a clinical stage company that is creating special purpose nanomaterials for antiviral therapy. The Company’s novel nanoviricide™ class of drug candidates and the nanoviricide™ technology are based on intellectual property, technology and proprietary know-how of TheraCour Pharma, Inc. The Company has a Memorandum of Understanding with TheraCour for the development of drugs based on these technologies for all antiviral infections. The MoU does not include cancer and similar diseases that may have viral origin but require different kinds of treatments.

The Company has obtained broad, exclusive, sub-licensable, field licenses to drugs developed in several licensed fields from TheraCour Pharma, Inc. The Company’s business model is based on licensing technology from TheraCour Pharma Inc. for specific application verticals of specific viruses, as established at its foundation in 2005.

Our lead drug candidate is NV-387, a broad-spectrum antiviral drug that we plan to develop as a treatment of RSV, COVID, Long COVID, Influenza, and other respiratory viral infections, as well as MPOX/Smallpox infections. Our other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. The Company cannot project an exact date for filing an IND for any of its drugs because of dependence on a number of external collaborators and consultants. The Company is currently focused on advancing NV-387 into Phase II human clinical trials.

NV-CoV-2 (API NV-387) is our nanoviricide drug candidate for COVID-19 that does not encapsulate remdesivir. NV-CoV-2-R is our other drug candidate for COVID-19 that is made up of NV-387 with remdesivir encapsulated within its polymeric micelles. The Company believes that since remdesivir is already US FDA approved, our drug candidate encapsulating remdesivir is likely to be an approvable drug, if safety is comparable. Remdesivir is developed by Gilead. The Company has developed both of its own drug candidates NV-CoV-2 and NV-CoV-2-R independently.

The Company is also developing drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides’ platform technology and programs are based on the TheraCour® nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. NanoViricides holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms in perpetuity for the treatment of the following human viral diseases: Human Immunodeficiency Virus (HIV/AIDS), Hepatitis B Virus (HBV), Hepatitis C Virus (HCV), Rabies, Herpes Simplex Virus (HSV-1 and HSV-2), Varicella-Zoster Virus (VZV), Influenza and Asian Bird Flu Virus, Dengue viruses, Japanese Encephalitis virus, West Nile Virus, Ebola/Marburg viruses, and certain Coronaviruses. The Company intends to obtain a license for RSV, Poxviruses, and/or Enteroviruses if the initial research is successful. As is customary, the Company must state the risk factor that the path to typical drug development of any pharmaceutical product is extremely lengthy and requires substantial capital. As with any drug development efforts by any company, there can be no assurance at this time that any of the Company’s pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance at this time that successful results against coronavirus in our lab will lead to successful clinical trials or a successful pharmaceutical product.

This press release contains forward-looking statements that reflect the Company’s current expectation regarding future events. Actual events could differ materially and substantially from those projected herein and depend on a number of factors. Certain statements in this release, and other written or oral statements made by NanoViricides, Inc. are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company’s control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. The Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Important factors that could cause actual results to differ materially from the company’s expectations include, but are not limited to, those factors that are disclosed under the heading “Risk Factors” and elsewhere in documents filed by the company from time to time with the United States Securities and Exchange Commission and other regulatory authorities. Although it is not possible to predict or identify all such factors, they may include the following: demonstration and proof of principle in preclinical trials that a nanoviricide is safe and effective; successful development of our product candidates; our ability to seek and obtain regulatory approvals, including with respect to the indications we are seeking; the successful commercialization of our product candidates; and market acceptance of our products.

The phrases “safety”, “effectiveness” and equivalent phrases as used in this press release refer to research findings including clinical trials as the customary research usage and do not indicate evaluation of safety or effectiveness by the US FDA.

FDA refers to US Food and Drug Administration. IND application refers to “Investigational New Drug” application. cGMP refers to current Good Manufacturing Practices. CMC refers to “Chemistry, Manufacture, and Controls”. CHMP refers to the Committee for Medicinal Products for Human Use, which is the European Medicines Agency’s (EMA) committee responsible for human medicines. API stands for “Active Pharmaceutical Ingredient”. WHO is the World Health Organization. R&D refers to Research and Development.

Contact:
NanoViricides, Inc.
info@nanoviricides.com

Public Relations Contact:
ir@nanoviricides.com

SOURCE: NanoViricides, Inc.

View the original press release on ACCESS Newswire

New preclinical findings highlight Telomir-1’s ability to reverse CDKN2A gene silencing by DNA methylation, reactivating this gene – often called the body’s natural “cell cycle brake.” These results build on prior STAT1 data, supporting Telomir-1’s profile as a potential first-in-class broad-spectrum DNA methylation reset therapy.

MIAMI, FLORIDA / ACCESS Newswire / September 9, 2025 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), a preclinical-stage biotechnology company developing therapies that target the root causes of biological aging, cancer, and age-related diseases, today announced new preclinical cancer data showing that Telomir-1 reverses DNA methylation of CDKN2A, a master tumor suppressor gene silenced in many aggressive cancers.

Reactivating Cancer’s Brakes
CDKN2A is one of the body’s most important natural defenses against cancer. Often called the “cell cycle brake,” this gene tells cells when to stop dividing and helps damaged cells self-destruct. In many cancers, CDKN2A is switched off by abnormal DNA methylation, leaving tumors free to grow unchecked. By resetting this methylation, Telomir-1 appears to turn the brake back on – restoring a critical safeguard that cancer cells had disabled.

Why DNA Methylation Matters
DNA methylation is a key epigenetic process that controls whether genes are switched on or off. In healthy cells, methylation helps regulate normal development and repair. In cancer, however, abnormal DNA methylation can silence critical tumor suppressor genes like CDKN2A and STAT1, allowing tumors to grow unchecked and evade the immune system. Similarly, widespread changes in DNA methylation patterns are recognized as one of the hallmarks of aging, contributing to the loss of cellular function and the onset of age-related diseases.

By demonstrating the ability to reduce DNA methylation of these important targets, Telomir-1 is showing potential to directly address these fundamental biological processes. This positions Telomir-1 not only as a novel oncology candidate, but also as a potential first-in-class longevity drug candidate targeting the root causes of aging and disease.

In aggressive human prostate cancer cell models (PC3 xenografts), Telomir-1 inhibited CDKN2A DNA methylation more effectively than both Rapamycin and chemotherapy. These results complement Telomir’s previously reported data showing that Telomir-1 also resets STAT1, a master regulator of immune surveillance. Together, these findings suggest that Telomir-1 may broadly reverse cancer-induced silencing of key tumor suppressors – tackling two of cancer’s most fundamental escape mechanisms: unchecked growth and immune evasion.

CEO Perspective
“This new evidence reinforces Telomir-1’s potential as a first-in-class longevity drug candidate that addresses the root causes of aging and age-related diseases through its ability to reset abnormal DNA methylation patterns,” said Erez Aminov, Chief Executive Officer of Telomir. “By demonstrating that Telomir-1 can reverse cancer-induced gene silencing in tumor suppressors such as CDKN2A and STAT1, we are beginning to show how epigenetic reprogramming may restore fundamental cellular functions that are disrupted in both cancer and aging.”

Scientific Perspective
“These findings are highly significant,” said Dr. Itzchak Angel, Chief Scientific Advisor at Telomir. “By simultaneously reactivating STAT1 and CDKN2A, Telomir-1 demonstrates the ability to reset epigenetic silencing across multiple tumor suppressor pathways. This dual restoration of both immune surveillance and cell cycle control represents a powerful mechanistic advance in cancer epigenetics and provides a compelling rationale for further translational development.”

Advancing Toward the Clinic
Telomir is actively assessing Telomir-1 across multiple aggressive cancers beyond prostate, with additional studies underway. The company’s pre-IND program is running in full gear, with CMC activities scaling up toward GMP production and IND-enabling studies ongoing as Telomir moves toward its first IND submission.

Cautionary Note Regarding Forward-Looking Statements
This press release, statements of Telomir’s management or advisors related thereto, and the statements contained in the news story linked in this release contain “forward-looking statements,” which are statements other than historical facts made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These risks and uncertainties include, but are not limited to, the potential use of the data from our studies, our ability to develop and commercialize Telomir-1 for specific indications, and the safety of Telomir-1.

Any forward-looking statements in this press release are based on Telomir’s current expectations, estimates and projections only as of the date of this release. These and other risks concerning Telomir’s programs and operations are described in additional detail in its Annual Report on Form 10-K for the fiscal year ended December 31, 2024, which are on file with the SEC and available at www.sec.gov. Telomir explicitly disclaims any obligation to update any forward-looking statements except to the extent required by law.

Contact Information
Helga Moya
info@telomirpharma.com
(786) 396-6723

SOURCE: Telomir Pharmaceuticals, Inc.

View the original press release on ACCESS Newswire

Inaugural Atlanta gathering brings together emerging leaders from major financial institutions

NEW YORK CITY, NY / ACCESS Newswire / September 9, 2025 / Vero Technologies, a leading provider of modular lending technology solutions, and Accend, an AI-powered credit and underwriting platform, today announced the launch of their NextGen Leaders Dinner Series, an exclusive forum designed to connect and empower the next generation of decision-makers in wholesale and asset finance.

The inaugural dinner, scheduled for September 17, 2025 in Atlanta, will bring together carefully selected rising executives from leading financial institutions including Stellantis Financial Services, GM Financial, Ally, Yamaha Motor Finance, and Northpoint Commercial Finance. The evening will feature an intimate roundtable discussion facilitated by Marguerite Watanabe, Principal of Connections Insights Consulting and a recognized industry thought leader.

“The asset finance industry is at an inflection point, and the leaders who will drive the next wave of innovation are already in our organizations today,” said John Mizzi, CEO and Co-founder of Vero Technologies. “This dinner series creates a unique space for these emerging leaders to connect, share perspectives, and shape the future of our industry together. We’re not just hosting a dinner – we’re building a community of changemakers.”

The NextGen Leaders Dinner Series focuses on professionals who are poised to become tomorrow’s decision-makers. The Atlanta event marks the first in a series of exclusive gatherings planned across major financial hubs throughout 2025 and 2026.

“Traditional industry events often miss the voices that will define our future,” said Pranjal Daga, CEO and Co-founder of Accend. “By bringing together these rising stars in an intimate setting, we’re facilitating the conversations and connections that will drive real transformation in how financial institutions approach credit, risk, and AI adoption.”

The invitation-only event reflects a growing recognition that the next generation of asset finance leaders needs forums designed specifically for their unique perspectives and challenges, separate from traditional industry conferences dominated by current C-suite executives.

For more information about the NextGen Leaders Dinner Series, contact info@vero-technologies.com.

About Accend
Accend is an AI-powered platform transforming credit and underwriting for modern financial institutions. By leveraging advanced machine learning and automation, Accend helps lenders make faster, more accurate credit decisions while reducing operational complexity.

For learn more, visit: www.withaccend.com.

About Vero Technologies
Vero Technologies is a leading financial technology platform for asset finance, providing end-to-end solutions for wholesale finance, trade finance, equipment finance, and title management. Vero’s modular platform enables lenders to streamline loan servicing, risk monitoring, and operational workflows, enhancing efficiency while reducing costs.

To learn more, visit: www.vero-technologies.com.

Contact: Jason Bartz, info@vero-technologies.com, 404-383-7048

SOURCE: Vero Finance Technologies

View the original press release on ACCESS Newswire

HOUSTON, TX / ACCESS Newswire / September 9, 2025 / Monkey Island LNG (“MILNG”) has signed a Memorandum of Understanding (MOU) with an investment-grade natural gas supplier to support Phase 1 (15.6 MTPA) of MILNG’s proposed LNG export facility located in Cameron Parish, Louisiana. While the supplier’s name remains confidential, the agreement validates the significant support Monkey Island LNG has attracted from top-tier natural gas suppliers. It also marks a pivotal step on the path towards Final Investment Decision (FID), advancing MILNG’s commercial progress and further de-risking its approximately $25 billion infrastructure plan.

“Securing a 20-year commitment from a major supplier represents another critical milestone for Monkey Island LNG,” said Greg Michaels, CEO of MILNG. “MILNG’s proprietary TrueCost LNG™ model is designed to upend traditional opaque LNG pricing by delivering full transparency, lower lifecycle costs, and complete alignment of interests between producer, buyer, and investors. We look forward to building on this partnership and welcoming additional suppliers to join us in reshaping how LNG projects are structured and contracted globally.”

The company’s transparent TrueCost LNG™ model continues to resonate with global partners seeking clarity in pricing, alignment in incentives, and long-term reliability in supply. The MILNG executive team is currently engaging with additional natural gas suppliers to expand its feedstock portfolio and further de-risk its project development.

“With the project’s technology selected, fuel supply secured, and market demand validated, we’re executing on all pillars required to advance the project to FID,” added Michaels. “This is LNG done differently – and done right.”

The project’s strategic location in Louisiana and its 246-acre site offers direct access to prolific natural gas production basins and deepwater marine access, enabling highly efficient logistics and low-cost LNG exports. MILNG sits approximately 70 miles from Henry Hub, the U.S. natural gas distribution hub and the benchmark pricing point for natural gas futures on the New York Mercantile Exchange (NYMEX).

Key Highlights

• 20-year gas supply secured with investment-grade supplier

• Built on MILNG’s proprietary TrueCost LNG™ model for cost transparency and commercial alignment

• Supports Phase 1 of MILNG’s 15.6 MTPA LNG export project

• Project is located near Henry Hub with direct access to prolific gas basins and deepwater marine routes

• MILNG facility will use ConocoPhillips’ (“COP”) Optimized Cascade® liquefaction technology

• Signed Master Services Agreement with McDermot for engineering and planning services

About Monkey Island LNG

Monkey Island LNG (“MILNG”) is a private company addressing the global energy crisis and growing demand for LNG through the development of critically needed U.S. natural gas infrastructure. Its flagship project, located on Monkey Island in Cameron Parish, Louisiana, sits just 2 miles inland from the Gulf of Mexico near abundant gas supply and features a proven and stable liquefaction technology of COP, an innovative commercial structure, and a low-cost construction plan leveraging an industry-proven EPC contractor. For more information, go to www.monkeyislandlng.com.

Forward-Looking Statement

This communication contains forward-looking statements within the meaning of applicable securities laws. All statements, other than statements of historical fact, are forward-looking statements and involve risks, uncertainties, and assumptions. These include, without limitation, statements regarding the expected scope, design, and timing of the Monkey Island LNG project; the execution, terms, and timing of definitive agreements; anticipated commercial progress; and other future events or developments.

Although Monkey Island LNG (“MILNG”) believes the expectations expressed in such forward-looking statements are reasonable, there can be no assurance that they will prove correct. Forward-looking statements are based on current assumptions and are subject to a number of risks and uncertainties, many of which are beyond our control. These risks include, but are not limited to: changes in market conditions, credit and capital markets, and industry norms; failure to successfully execute or complete contracts; changes in project scope, design, or schedules; availability of qualified personnel and resources; contract modifications, cancellations, or disputes; and other factors that could cause actual results to differ materially from those expressed or implied.

Forward-looking statements speak only as of the date of this communication. MILNG undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances after the date hereof, except as required by applicable law. Readers are cautioned not to place undue reliance on forward-looking statements.

Press Contacts

For Monkey Island LNG:
Greg Michaels, CEO, Monkey Island LNG
Greg.m@mkyisland.com
949-636-5900

SOURCE: Monkey Island LNG

View the original press release on ACCESS Newswire

– Gemini normalized the inflammatory response at the cellular level in stage 3 and 4 CKD patients –

– Gemini could potentially revolutionize the treatment of acute and chronic inflammatory disease –

Data discussion webcast/conference call will be held on Wednesday, September 10^th at 8:30 am Eastern Time

SAN DIEGO, CA / ACCESS Newswire / September 9, 2025 / Revelation Biosciences, Inc. (NASDAQ:REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company focused on rebalancing inflammation, today announced positive safety and activity data for its Phase 1b PRIME clinical study in stage 3 and 4 chronic kidney disease (CKD) patients. The primary endpoint to evaluate the safety and tolerability of escalating doses of Gemini was met.

More importantly, Gemini significantly reduced inflammatory activity and restored normal cellular response to stimuli as measured in peripheral blood mononuclear cells (PBMCs) isolated from patients at predose, 2, 24, and 168 hours post-dose, demonstrating Gemini’s ability to durably rebalance the inflammatory process at the cellular level. Revelation will host a corporate update webcast/conference call on Wednesday, September 10^th at 8:30 am Eastern Time to review this top-line data and the potential impact of the use of Gemini for the treatment of acute and chronic inflammatory diseases.

“The activity observed with a single dose of Gemini in patients is shocking,” said Principal Investigator Adam Horeish, MD, Balboa Research. “This effect suggests a meaningful step forward in addressing the underlying immune dysregulation observed in patients with chronic kidney disease, and I am intrigued by the potential of Gemini to treat multiple types of acute and chronic inflammation.”

“The results from this Phase 1b study represent a possible breakthrough in the treatment of inflammation,” said Principal Investigator Pablo Pergola, MD, PhD,Research Director at Clinical Advancement Center, PLLC. “By addressing the inflammatory component of CKD, we may be able to improve patient outcomes and bring meaningful benefit to those living with this challenging condition. We look forward to working with the Revelation team to advance Gemini as a potential treatment for CKD.”

“The clear results from the PRIME study demonstrate the power of Gemini to elicit trained immunity,” said Julia K. Bohannon, Ph.D., Associate Professor, Department of Anesthesiology, Department of Pathology, Microbiology, and Immunology, Vanderbilt University Medical Center. “It is highly validating to see results consistent with the findings from our animal studies, as I would have expected. The strength of the effect of a single dose reinforces my confidence in the potential of Gemini as a promising treatment for burn patients.”

The PRIME study enrolled 40 patients from 32 to 78 years of age, at 3 US clinics located in San Diego and San Antonio, specializing in the care of patients with CKD. A total of 5 cohorts (8 patients per cohort, 6 treated/2 placebo) at 4 dose levels were enrolled: a subtherapeutic dose, a low dose, the target dose (cohorts 3 and 4), and a high dose – an extension protocol was conducted to collect additional PBMC and biomarker samples in 8 Gemini naive or secondary naive patients. The primary endpoint was evaluation of safety.

In addition to safety measures, patient PBMCs were isolated predose and at 2, 24, and 168 hours post-dose. PBMCs were analyzed ex vivo for background inflammation by measurement of IL-1β, TNF-α, IL-6, IL-10, and IL-1RA. Cells were also assessed for response to stimulation by lipopolysaccharide (LPS, also known as endotoxin) or high mobility group box-1 protein (HMGB1). Subgroup analysis divided patients into two categories, those with PBMCs of minimal background inflammation activity (£40 pg/mL IL-1β) and normal response to stimuli, and those with significant background inflammation activity (>40 pg/mL IL-1β) and no response to stimuli. Approximately 50% of patients were in each group.

In patients with high background PBMC activity, Gemini significantly reduced inflammation relative to placebo patient PBMCs post dose (IL-1β: p0.01; TNF-α: p=0.05; IL-6: p0.01; IL-10: p0.01; IL-1RA: p0.001) and remained significantly below their baseline value through 7 days. Background inflammation was reduced to levels comparable to PBMCs isolated from healthy subjects.

Additionally, Gemini was able to demonstrate correction of the immunoparalysis typical to chronic disease. Gemini significantly increased the responsiveness to LPS stimulation in high background patient PBMCs relative to placebo at all timepoints (IL-1β: p0.0001; TNF-α: p0.002; IL-6: p0.0002; IL-10: p=0.09; IL-1RA: p0.01). Gemini also significantly increased the responsiveness of patient PBMCs with high background vs placebo patient PBMCs with high background at all time-points to HMGB1 stimulation (IL-1β: p0.05; TNF-α: p0.01; IL-6: p0.01; IL-10: p0.05; IL-1RA: p0.002). The increased responsiveness was comparable to PBMCs isolated from healthy subjects. These results show the ability of Gemini to restore normal cell function, even as far as one week after a single dose.

For the low background patients, as expected, Gemini does not increase inflammatory activity. Additional analysis on the effect of LPS or HMGB-1 stimulation is ongoing.

Gemini administration was well-tolerated at the target dose (established as the maximum tolerated dose in healthy volunteers) with all events reported as mild (Grade I). Adverse events observed at the target dose included transient headache, chills, loose stool, and body aches. Three adverse events at the highest dose (above the target dose) were reported as severe (Grade III), and included chills, nausea and vomiting, all resolving in 3 hours or less. Other reported events were either mild (Grade I) or moderate (Grade II). All events corresponded with the previous healthy volunteer study, as well as with preclinical findings, and are consistent with the expected pharmacology of the drug. No serious adverse events were reported. Gemini administration did not result in clinically significant trends in clinical safety blood or urinalysis parameters (aside from expected immune cell mobilization). There were no clinically significant changes or trends in vital sign parameters or ECG assessments following administration of Gemini.

“The results of the PRIME study demonstrate the potential of Gemini to be a game-changer in the treatment of acute and chronic inflammation,” said James Rolke, Chief Executive Officer of Revelation. “We look forward to our scheduled End of Phase 1 meeting with the FDA later this year to discuss the advancement of this exciting program.”

The September 10^th webcast at 8:30 am Eastern Time can be accessed here, or to call in, please dial 888-506-0062 (toll free in the US), +1 973-528-0011 (if International) and use participant access code 289672. A copy of the slides being presented in the webcast can be found on Revelation’s website here.

Revelation will seek to publish these results and those from ongoing additional data analysis. For more information please visit www.RevBiosciences.com.

About CKD

Chronic kidney disease is a pervasive problem in the United States and world-wide. CKD is due to chronic inflammation and can be initiated and propagated in several ways. One prevalent condition is the high blood sugar levels associated with diabetes (either Type 1 or Type 2). High blood sugar is toxic to kidney cells creating stress which imitates the inflammatory process leading to the demise of these cells with subsequent fibrosis, ultimately resulting in continuous loss of kidney function over time. High arterial blood pressure is another source of stress that initiates the inflammatory process leading to CKD. Other risk factors include heart disease, obesity, family history of CKD, or advanced age. Progression of chronic kidney damage often leads to end stage renal disease with the need for renal replacement therapy (dialysis or transplantation), resulting in significant morbidity and mortality for affected patients. Kidney disease is a leading cause of death in the United States.

About Gemini

Gemini is the Company’s proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD^®), a toll-like receptor 4 (TLR4) agonist. TLR4 stimulation with Gemini rebalances the innate immune response. Gemini is being developed as a treatment and a prevention of acute and chronic diseases associated with dysregulated inflammation.

About Revelation Biosciences, Inc.

Revelation Biosciences, Inc. is a clinical stage life sciences company focused on rebalancing inflammation using its proprietary formulation Gemini. Revelation has multiple ongoing programs to evaluate Gemini, including as a prevention for post-surgical infection, as prevention for acute kidney injury and for the treatment of chronic kidney disease.

For more information, please visit www.RevBiosciences.com.

Forward-Looking Statements

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts. These forward-looking statements are generally identified by the words “anticipate”, “believe”, “expect”, “estimate”, “plan”, “outlook”, and “project” and other similar expressions. We caution investors that forward-looking statements are based on management’s expectations and are only predictions or statements of current expectations and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from those anticipated by the forward-looking statements. Revelation cautions readers not to place undue reliance on any such forward looking statements, which speak only as of the date they were made. The following factors, among others, could cause actual results to differ materially from those described in these forward-looking statements: the ability of Revelation to meet its financial and strategic goals, due to, among other things, competition; the ability of Revelation to grow and manage growth profitability and retain its key employees; the possibility that the Revelation may be adversely affected by other economic, business, and/or competitive factors; risks relating to the successful development of Revelation’s product candidates; the ability to successfully complete planned clinical studies of its product candidates; the risk that we may not fully enroll our clinical studies or enrollment will take longer than expected; risks relating to the occurrence of adverse safety events and/or unexpected concerns that may arise from data or analysis from our clinical studies; changes in applicable laws or regulations; expected initiation of the clinical studies, the timing of clinical data; the outcome of the clinical data, including whether the results of such study is positive or whether it can be replicated; the outcome of data collected, including whether the results of such data and/or correlation can be replicated; the timing, costs, conduct and outcome of our other clinical studies; the anticipated treatment of future clinical data by the FDA, the EMA or other regulatory authorities, including whether such data will be sufficient for approval; the success of future development activities for its product candidates; potential indications for which product candidates may be developed; the ability of Revelation to maintain the listing of its securities on NASDAQ; the expected duration over which Revelation’s balances will fund its operations; and other risks and uncertainties described herein, as well as those risks and uncertainties discussed from time to time in other reports and other public filings with the SEC by Revelation.

Company Contact

Mike Porter
Investor Relations
Porter LaVay & Rose Inc.
Email: mike@plrinvest.com

Chester Zygmont, III
Chief Financial Officer
Revelation Biosciences Inc.
Email: czygmont@revbiosciences.com

SOURCE: Revelation Biosciences, Inc.

View the original press release on ACCESS Newswire

VANCOUVER, BC / ACCESS Newswire / September 9, 2025 / Avino Silver & Gold Mines Ltd. (TSX:ASM)(NYSE American:ASM)(FSE:GV6) a long-standing silver producer in Mexico, is proud to announce that Avino has been included in the Toronto Stock Exchange’s 2025 TSX30™. Avino has distinguished itself by reaching the 5^th position on the TSX30 2025 ranking, which is a flagship program recognizing the 30 top-performing TSX stocks on a dividend-adjusted share price appreciation over a three-year period.

“I am extremely pleased that Avino has been recognised by the TSX in 2025,” said David Wolfin, Avino’s President and CEO. “For the three years ended June 30, 2025, Avino’s share price performance has increased 610% and market capitalization has increased 778%. These achievements reflect the decisive steps we took to prioritize Avino’s transformational growth and our plans to go from one to three producing assets by 2029. These results are a testament to the commitment, determination and hard work of all Avino’s employees. Our focus has been on advancing our operations in Mexico and strengthening our silver, gold, and copper profile as we progress toward becoming a leading intermediate producer. We remain focused on our growth objectives and committed to delivering long-term value for our shareholders and stakeholders.”

“The 2025 TSX30™ captures the evolution of our capital markets, where companies are scaling to compete globally for market share and capital. These top performers represent diverse sectors unified by strategic positioning and proven execution,” said Loui Anastasopoulos, CEO, Toronto Stock Exchange. “Together, this list highlights how companies are capitalizing on prevailing economic trends, with investors prioritizing sustainable value creation from companies with proven business models and strong cash flow generation, whether in transformative technologies or our world-class resource and industrial sectors.”

About Avino

Avino is a silver producer from its wholly owned Avino Mine near Durango, Mexico. The Company’s silver, gold and copper production remains unhedged. The Company intends to maintain long term sustainable and profitable mining operations to reward shareholders and the community alike through our growth at the historic Avino Property and the strategic acquisition of the adjacent La Preciosa which was finalized in Q1 2022. Early in 2024, the pre-feasibility Study on the Oxide Tailings Project was completed. This study is a key milestone in our growth trajectory. As part of Avino’s commitment to adopting sustainable practices, we have been operating a dry-stack tailings facility for more than two years with excellent results. We are committed to managing all business activities in a safe, environmentally responsible, and cost-effective manner, while contributing to the well-being of the communities in which we operate. We encourage you to connect with us on X (formerly Twitter) at @Avino_ASM and on LinkedIn at Avino Silver & Gold Mines. To view the Avino Mine VRIFY tour, please click here.

For Further Information, Please Contact:

Investor Relations
Tel: 604-682-3701
Email: IR@avino.com

This news release contains “forward-looking information” and “forward-looking statements” (together, the “forward looking statements”) within the meaning of applicable securities laws and the United States Private Securities Litigation Reform Act of 1995, including the mineral resource estimate for the Company’s Avino Property, including La Preciosa, located near Durango in west-central Mexico (the “Avino Property”) with an effective date of October 16, 2023 and can be viewed within Avino’s latest technical report dated February 5, 2024 for the Pre-feasibility Study and references to to Measured, Indicated Resources, and Proven and Probable Mineral Reserves referred to in this press release. This information and these statements, referred to herein as “forward-looking statements” are made as of the date of this document. Forward-looking statements relate to future events or future performance and reflect current estimates, predictions, expectations or beliefs regarding future events and include, but are not limited to, statements with respect to: (i) the estimated amount and grade of mineral reserves and mineral resources, including the cut-off grade; (ii) estimates of the capital costs of constructing mine facilities and bringing a mine into production, of operating the mine, of sustaining capital, of strip ratios and the duration of financing payback periods; (iii) the estimated amount of future production, both ore processed and metal recovered and recovery rates; (iv) estimates of operating costs, life of mine costs, net cash flow, net present value (NPV) and economic returns from an operating mine; and (v) the completion of the full Technical Report, including a Preliminary Economic Assessment, and its timing. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives or future events or performance (often, but not always, using words or phrases such as “expects”, “anticipates”, “plans”, “projects”, “estimates”, “envisages”, “assumes”, “intends”, “strategy”, “goals”, “objectives” or variations thereof or stating that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative of any of these terms and similar expressions) are not statements of historical fact and may be forward-looking statements. These forward-looking statements are made as of the date of this news release and the dates of technical reports, as applicable. Readers are cautioned not to place undue reliance on forward-looking statements, as there can be no assurance that the future circumstances, outcomes or results anticipated in or implied by such forward-looking statements will occur or that plans, intentions or expectations upon which the forward-looking statements are based will occur. While we have based these forward-looking statements on our expectations about future events at the date that such statements were prepared, the statements are not a guarantee that such future events will occur and are subject to risks, uncertainties, assumptions and other factors which could cause events or outcomes to differ materially from those expressed or implied by such forward-looking statements.

SOURCE: Avino Silver & Gold Mines Ltd.

View the original press release on ACCESS Newswire

In an historic moment for regional solidarity and leadership, West African Ministers of Health pledge their joint commitment to advance the development of, and readiness for, much-needed vaccines against Lassa fever in recognition of the significant threat to regional health security posed by the disease.

ABIDJAN, CI / ACCESS Newswire / September 9, 2025 / On September 8, 2025, Ministers of Health from across the region gathered for high-level talks convened by the West African Health Organisation (WAHO) and Dr. Muhammad Ali Pate, the Coordinating Minister of Health and Social Welfare of Nigeria, as co-leads of the Lassa fever Vaccine Coalition, and Mr. Pierre N’Gou Dimba, Minister of Health, Public Hygiene and Universal Health Coverage of the ​Republic of Côte d’Ivoire, as host of the Lassa fever International Conference in Abidjan. The meeting was supported by global pandemic preparedness institution, the Coalition for Epidemic Preparedness Innovations (CEPI) and the International AIDS Vaccine Initiative (IAVI), a non-profit scientific research organisation. The Ministers of Health endorsed a communiqué that reinforces the region’s shared leadership in confronting a virus that is endemic to West Africa and causes significant health, economic and societal harm.

Despite its devastating impact, there are currently no licensed vaccines to protect against Lassa fever. The most advanced Lassa fever vaccine candidate has been developed by IAVI with funding from CEPI and the European & Developing Countries Clinical Trials Partnership. IAVI’s promising vaccine candidate is currently being evaluated in a Phase IIa clinical trial to evaluate the vaccine’s safety and immunogenicity in Ghana, Liberia and Nigeria – the most advanced study of a Lassa fever vaccine to take place anywhere in the world.

Through the communiqué, the Ministers reaffirmed their political endorsement of accelerating Lassa fever vaccine readiness as a regional strategic health priority and a cornerstone of pandemic preparedness, underscoring its dual role in strengthening national systems and collective resilience. They recognised that Lassa fever could serve as a model towards broader integration and coordination of financing efforts. They committed to supporting the development of IAVI’s Lassa vaccine candidate rVSVΔG-LASV-GPC^[1] through a collaborative co-funding approach and joint action to mobilise and secure resources through advocacy and regional coordination. They pledged to strengthen country and regional platforms to ensure that clinical trial sites, laboratories, regulatory authorities and community engagement efforts across West Africa are ready to enable the late-stage clinical research needed to advance a Lassa fever vaccine to licensure and to bolster the region’s response to other epidemic and pandemic disease threats.

Dr. Muhammad Ali Pate, Coordinating Minister for Health and Social Welfare of Federal, Republic of Nigeria, said: “For decades, Lassa fever has silently taken lives, eroded livelihoods, and tested the resilience of our health systems. Here in Abidjan, West Africa is showing a new path: countries uniting not only to call for a vaccine, but to co-finance and prepare the systems that will make it real. In Nigeria, through the Health Sector Renewal Initiative, we are investing in laboratories, surveillance, and regulatory readiness – efforts that complement and strengthen regional solidarity. What we commit to today is bigger than one disease; it is a statement that Africa can mobilise its science, align its financing, and contribute decisively to global preparedness. If we hold this course, the legacy will be measured in lives protected and in a continent that helped safeguard the world from the pandemics of tomorrow.”

Dr. Melchior Athanase J. C. Aissi, Director General of WAHO, said:”WAHO is proud to convene and coordinate this landmark commitment. ECOWAS Ministers have agreed not just to endorse a vaccine, but to co-finance it together – showing that West Africa is ready to lead on solutions to Lassa fever and pandemic threats. Regional solidarity is our greatest asset, and WAHO will continue to drive this united approach.”

Dr. Richard Hatchett, CEO of CEPI, said: “The prospect of protection against this dreadful disease is closer than ever before. CEPI is committed to working in close partnership with West African leaders to bolster regional health security by advancing the licensure of the first ever Lassa vaccine and strengthening the region’s capabilities to respond to other epidemic or pandemic threats.”

Dr. Mark Feinberg, IAVI President and CEO, said: “We welcome this unprecedented opportunity to advance IAVI’s promising Lassa fever vaccine candidate in close partnership with West African governments, Institut Pasteur de Dakar – a regionally based manufacturer – and regional scientific and public health leaders. By signing this communiqué, we are not just one step closer to an affordable and accessible Lassa vaccine; we are building a global health partnership that can provide a new model to advance the development, and to ensure sustainable and affordable supply of, vaccines targeting diseases where there is no commercial incentive for private, for-profit companies to invest.”

Signatories of the communiqué include Ministers of Health or their representatives from the Republic of Benin, Republic of Cabo Verde, Republic of Côte d’Ivoire, Republic of Ghana, Republic of Guinea-Bissau, Republic of the Gambia, Republic of Liberia, Federal Republic of Nigeria, Republic of Senegal, Republic of Sierra Leone and the Togolese Republic.

As next steps, the Ministers agreed to coordinate with countries to ensure capabilities are in place to support late-stage vaccine development and to refine the regional financing approach. In support of the latter, WAHO, CEPI and IAVI will convene a working group of countries to align on resource mobilisation.

Hundreds of thousands of people in West Africa are estimated to be affected by Lassa fever each year, with the disease causing almost 4,000 deaths and $110 million in productivity losses in the region annually. Symptoms range from mild headache to vomiting, swelling and widespread bleeding which can be fatal. In those that recover, hearing loss is commonly reported. The potential impact of the disease is set to worsen, with modelling research predicting up to 600 million people could be at risk of Lassa fever infection by 2050 as a result of climate change and population growth.

The 2^nd Lassa fever International Conference runs from 8-11 September 2025, under the theme “Beyond Borders: Strengthening Regional Cooperation to Combat Lassa Fever and Emerging Infectious Diseases”. The landmark event brings together scientists, public health experts, vaccine developers, policymakers, civil society and regional stakeholders to share insights, review progress and forge new partnerships aimed at accelerating vaccine development and strengthening Lassa fever control efforts.

For further information, kindly contact:

WAHO Communications Office: Email: communication@wahooas.org
CEPI: Email: press@cepi.net | Phone: +44 7387 05T 5214
IAVI: Email: rcatlos@iavi.org

About West African Health Organisation (WAHO)
The West African Health Organisation (WAHO) is the Specialised Health Institution of ECOWAS, established in 1987 to coordinate regional health initiatives across West Africa. Headquartered in Bobo-Dioulasso, Burkina Faso, WAHO works to harmonise health policies, pool resources, and foster collaboration among Member States. Its core mandate is to improve health standards and strengthen health systems across the sub-region. Guided by its vision, WAHO strives to be a proactive driver of regional health integration, delivering high-impact and cost-effective health interventions for West African communities.

About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations. Its mission is to accelerate the development of vaccines and other biologic countermeasures against epidemic and pandemic threats so they can be accessible to all people in need. CEPI has supported the development of more than 50 vaccine candidates or platform technologies against multiple known high-risk pathogens or a future Disease X. Central to CEPI’s pandemic-beating five-year plan for 2022-2026 is the ‘100 Days Mission’ to accelerate the time taken to develop safe, effective, globally accessible vaccines against new threats to just 100 days.

About IAVI
IAVI is a non-profit scientific research organization dedicated to addressing global, unmet health challenges including HIV, tuberculosis, and a range of emerging infectious diseases. Its mission is to translate scientific discoveries into affordable, globally accessible public health tools. Read more at www.iavi.org.

SOURCE: IAVI

View the original press release on ACCESS Newswire

Energy Storage Systems will be based on Electrovaya’s proven technology and includes cells, modules and packs manufactured in the USA, enabling strong ITC Incentives

Initial systems offer over 2MWh of storage capacity in a 20′ containerized format with leading cycle life and featuring Electrovaya’s proprietary safety technologies

New product will target a wide variety of energy storage applications with strong initial interest from existing high profile customer base

TORONTO, ON / ACCESS Newswire / September 9, 2025 / Electrovaya Inc. (“Electrovaya” or the “Company”) (Nasdaq:ELVA)(TSX:ELVA), a lithium-ion battery technology and manufacturing company, today announced the commercial launch of its next-generation Energy Storage Systems (“ESS”), developed to address the growing demand for safe, durable, and cost-effective stationary energy storage solutions.

Electrovaya’s ESS products are built on the Company’s proprietary Infinity Technology, which delivers:

• Industry-leading cycle life: enabling significantly longer service duration and reducing replacement frequency.

• Enhanced safety: with robust thermal stability and fail-safe architecture that minimize thermal and failure risk.

• Lower life cycle cost: through reduced operating expenses and extended system longevity.

• These benefits translate into superior durability, safer customer assets, and stronger economic returns, making the systems ideally suited for grid support, renewable energy integration, microgrids, backup power, data centers, hyperscalers and behind-the-meter applications.

U.S. Manufacturing and Vertical Integration

Electrovaya’s ESS will be manufactured in the United States at its vertically integrated facility in Jamestown, New York. The Company controls production from the cell level through to complete systems, ensuring consistent quality, supply chain security, and eligibility for domestic content incentives under U.S. policy frameworks, including under the recent One Big Beautiful Bill Act (OBBA). Under this provision, Electrovaya’s ESS are expected to be eligible for 30-40% Investment Tax Credits.

This vertical integration also supports scalability as demand accelerates for large-format ESS, positioning Electrovaya as a strategic supplier in North America’s rapidly expanding energy storage market.

Strategic Market Opportunity

The global stationary energy storage market is already large and projected to grow significantly over the next decade, fueled by increasing renewable energy adoption, grid modernization efforts, and growing demands for resiliency. Electrovaya’s Infinity-based ESS solutions offer a differentiated value proposition for data centers, hyperscalers, and behind-the-meter (BTM)applications. Compared to conventional lithium-ion systems, Electrovaya’s entry leverages its proven Infinity technology which enables significantly improved safety and longevity, key performance attributes for energy storage use cases where safety, life cycle cost, and reliability are critical.

“Electrovaya has a long track record of developing advanced lithium-ion systems for mission-critical applications,” saidDr. Raj DasGupta, CEO of Electrovaya. “With our ESS launch, we are extending these capabilities into the stationary market, offering customers a technology that is safer, lasts longer, and delivers the lowest total cost of ownership.”

Availability

Electrovaya’s new ESS products are available for order in North America, with initial deployments expected in 2026 and larger scale deliveries in 2027. The Company is engaged with customers across multiple sectors, including with its existing customers of material handling battery products.

Electrovaya will be exhibiting at the RE+ Expo in Las Vegas, Nevada, from September 9-11, 2025, at Booth F17153 in Caesars Forum. Stop by to explore our Infinity Battery solutions, engineered for safety, longevity, and sustainability.

Investor and Media Contact:

Jason Roy
VP, Corporate Development and Investor Relations
Electrovaya Inc.
905-855-4618 / jroy@electrovaya.com

About Electrovaya Inc.

Electrovaya Inc. (NASDAQ:ELVA)(TSX:ELVA) is a pioneering leader in the global energy transformation, focused on contributing to the prevention of climate change by supplying safe and long-lasting lithium-ion batteries. The Company has extensive IP and designs, develops and manufactures proprietary lithium-ion batteries and battery systems for energy storage and heavy duty electric vehicles based on its Infinity Battery Technology Platform. This technology offers enhanced safety and industry leading battery longevity. The Company is also developing next generation solid state battery technology at its Labs division. Headquartered in Ontario, Canada, Electrovaya has two operating sites in Canada and has acquired a 52-acre site with a 135,000 square foot manufacturing facility in New York state for its planned gigafactory. To learn more about Electrovaya, please explore www.electrovaya.com.

Forward-Looking Statements

This press release contains forward-looking statements relating to announcements regarding cell performance, cycle life, longevity, projected performance, extrapolated cycle life, energy density, relative performance compared to competitors, planned production in Jamestown New York, ability to start production in Jamestown in the expected timeframe, planned 54Ah and 51Ah lithium-ion ceramic cell in product lines in 2025 and 2026, use in commercial vehicle and energy storage applications, deliveries of energy storage systems in 2026, scaled deliveries in 2027, energy density, cell performance, safety, cost of ownership, life cycle cost, and can generally be identified by the use of words such as “may”, “will”, “could”, “should”, “would”, “likely”, “possible”, “expect”, “intend”, “estimate”, “anticipate”, “believe”, “plan”, “objective”, “seed”, “growing” and “continue” (or the negative thereof) and words and expressions of similar import. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, such statements involve risks and uncertainties, and undue reliance should not be placed on such statements. Certain material factors and assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Statements with respect to solid state batteries, battery technologies and production roadmaps, are based on an assumption that the Company’s customers and users will deploy its products in accordance with communicated intentions, and the Company has investment capital to deploy. Important factors that could cause actual results to differ materially from expectations include but are not limited to macroeconomic effects on the Company and its business and on the Company’s customers, including inflation and tightening credit availability due to systemic bank risk, economic conditions generally and their effect on consumer demand and capital availability, labour shortages, supply chain constraints, the potential effect of health based restrictions in Canada, the US and internationally on the Company’s ability to produce and deliver products, and on its customers’ and end users’ demand for and use of products, which effects are not predictable and may be affected by additional regional outbreaks and variants, and other factors which may cause disruptions in the Company’s supply chain and Company’s capability to deliver and develop its products. Additional information about material factors that could cause actual results to differ materially from expectations and about material factors or assumptions applied in making forward-looking statements may be found in the Company’s Annual Information Form for the year ended September 30, 2024 under “Risk Factors”, and in the Company’s most recent annual Management’s Discussion and Analysis under “Qualitative And Quantitative Disclosures about Risk and Uncertainties” as well as in other public disclosure documents filed with Canadian securities regulatory authorities. The Company does not undertake any obligation to update publicly or to revise any of the forward-looking statements contained in this document, whether as a result of new information, future events or otherwise, except as required by law.

SOURCE: Electrovaya, Inc.

View the original press release on ACCESS Newswire

TAMPA, FL / ACCESS Newswire / September 9, 2025 / Infotect Design Solutions, is proud to announce the launch of Givsync, a powerful cloud-based application built to help non-profit organizations streamline operations, improve service delivery, and maximize community impact.

Now available on the Microsoft Marketplace, Givsync is built for 501(c)(3) organizations that distribute goods or offer retail-style services without cash transactions. The platform streamlines appointment scheduling, customer management, inventory tracking, and reporting-reducing manual tasks and empowering teams to focus on their mission.

With affordable subscription options tailored for small and medium nonprofits, Givsync makes it easy to adopt powerful technology without straining your budget. Start simplifying your operations and amplifying your impact-explore Givsync today on Microsoft Marketplace.

Givsync was built with purpose. The team behind Givsync understands the unique challenges nonprofits face and is committed to delivering technology that helps them grow, serve, and succeed. Built on Microsoft’s Power Platform, Givsync not only integrates seamlessly with Microsoft 365 but also unlocks the ability to incorporate advanced AI capabilities. This foundation allows nonprofits to automate workflows, gain predictive insights, and personalize engagement-making Givsync a scalable, intelligent solution tailored to the evolving needs of mission-driven organizations.

Whether managing a food pantry, donation center, or community outreach program, Givsync empowers organizations to operate more efficiently and deliver greater impact.

Ideal for:

• 501(c)(3) organizations

• Agencies offering goods or retail experiences without a cash transaction

• Teams needing efficient booking, scheduling, and customer notifications

Givsync is now available for demo and deployment. To learn more or explore how Givsync can support your organization, visit www.givsync.com or contact engagement@givsync.com.

About Infotect Design Solutions
Founded in 2000, Infotect Design Solutions is a Florida-based IT consulting firm specializing in cloud applications, workflow automation, and managed services. With over two decades of partnership with Microsoft, Infotect empowers small and mid-sized organizations to embrace digital transformation through secure, scalable, and user-friendly technology solutions. Service verticals include non-profits, medical, construction and local government with clients internationally. The company’s mission is rooted in delivering exceptional service, fostering long-term client relationships, and helping organizations achieve their goals through innovation and strategic IT support.

SOURCE: Infotect Design Solutions

View the original press release on ACCESS Newswire

New integrations with Mimir, Iconik, Embrace, and Broadteam enhance interoperability and streamline workflows. Telestream to showcase these and more innovations at IBC2025.

NEVADA CITY, CA / ACCESS Newswire / September 9, 2025 / Telestream, a global leader in media workflow technologies, has announced that Vantage now integrates directly with next-generation media platforms, including Mimir, Iconik, Embrace, and Broadteam, to support evolving media workflows and advance interoperability across modern media supply chains. The integrations enable media organizations to automate critical workflows, scale operations on demand, and connect cloud and on-premises environments with precision. Telestream will demonstrate these integrations alongside its AI enhancements, Global Ingest, and Measurement capabilities at IBC2025, Stand 7.B21.

“Increasingly, our customers need open, scalable workflows that meet them where they are, whether that’s on-prem, in the cloud, or both,” said Charlie Dunn, Executive Vice President of Products at Telestream. “By integrating with these future-ready platforms, we’re delivering a cohesive path to automation and interoperability that improves speed, quality, and visibility across the entire media lifecycle.”

These integrations strengthen Telestream’s Global Ingest strategy, unifying live, camera card, and file-based ingest into one intelligent pipeline enriched with structured metadata, accelerating collaboration, improving searchability, and ensuring content flows seamlessly across on-prem, cloud, and hybrid operations.

Vantage + Mimir: Modern, cloud-based media asset management

Vantage and Mimir together enhance cloud-native media management for news, sports, and enterprise content operations by automating processing within Mimir’s AI-powered, browser-based platform. When content enters a Mimir input bucket via live ingest, upload, or another workflow, Vantage will automatically run ingest, QC, and metadata creation in the background. This enables editors and producers to access, search, and work with media in near real-time without manual delays.

Ideal for live-to-VOD workflows, the integration ensures content is processed, indexed, and ready for creative use quickly and accurately, supporting fast-turn, distributed production environments and bridging the gap between technical processing and editorial decision-making.

Vantage + Iconik: Real-time collaboration for decentralized teams

The Vantage integration with Iconik supports hybrid workflows that unify local and cloud storage in a single searchable environment. Triggered by folder placement or metadata, Vantage can handle ingest, proxy creation, QC, and push processed assets back to Iconik for review and distribution. This allows decentralized teams to collaborate in real time without duplicating effort or moving large files unnecessarily.

The Iconik integration also supports growing media workflows, enabling editors to work in Adobe Premiere Pro with content as it’s being captured, while Vantage mirrors originals to the cloud for remote access. This hybrid, cloud-connected approach reduces complexity, speeds turnaround, and supports scalable, metadata-driven workflows, ideal for distributed teams, remote post-production, and high-volume environments.

Learn more about Vantage’s integration with Mimir and Iconik.

Vantage + Embrace: Intuitive, No-Code Visual Orchestration

Integrated with Vantage, Embrace Pulse-IT brings simplicity to complex, multi-step workflows by combining Vantage’s robust media processing with Embrace’s low-code/no-code visual orchestration. Embrace’s intuitive interface enables teams to design, trigger, and monitor workflows seamlessly, from ingest and QC to transcoding and metadata transformation, all without coding, while Vantage handles the heavy processing. Together, these tools put sophisticated media automation within reach of non-developers, enabling faster and more adaptable workflows across cloud, hybrid, and on-premises environments.

This pairing supports complex use cases like live news and sports, multi-stage post-production, and large-scale OTT delivery, with conditional logic, automated routing, and human-in-the-loop approvals where needed. The result is greater speed, flexibility, and visibility, reducing manual effort and engineering reliance while ensuring quality, compliance, and agility in rapidly changing media operations.

Learn more about Vantage’s integration with Embrace.

Vantage + Broadteam: File & live logging, instant clip creation, and archiving

A seamless integration between Skylog and Vantage transforms live ingest and media indexation. Operators can enrich growing files in real time with manual or automated metadata, ensuring every key moment is captured with precision. Through an intuitive, web-based interface with AI assistance, operators can tag, annotate, organize, and rate content as it happens. From a three-pointer in basketball to a pivotal reality-show reveal, enriched, timecode-linked metadata travels seamlessly through the workflow.

This collaboration unites Skylog’s strengths in live and file logging, clipping, and AI-powered indexation with Vantage’s industry-leading transcoding and workflow automation. For sports and entertainment organizations, the result is clear: reduced manual processes, lower production costs, and accelerated turnaround times for editing processes, highlights, and archive enrichment. With Skylog x Vantage, broadcasters gain the agility to scale remote and on-premises workflows.

Powering Modern Media Creation Through Interoperability

Media companies are rapidly adopting modern media workflows that can be deployed across on-prem, cloud, and hybrid environments. Managing ingest, transcoding, metadata, QC, and delivery across multiple systems is complex, but integrations with platforms like Mimir, Iconik, Embrace, and Broadteam bring new agility.

These browser-based solutions enable creative teams to work from anywhere, while Telestream Vantage delivers proven, trusted, and reliable media processing behind the scenes. Together, they streamline every stage of the pipeline, reducing manual effort, accelerating turnaround, and ensuring high-quality content reaches audiences quickly and efficiently. Early adopters are using the integrations to turn around highlights packages in minutes, centralize QC for multi-market delivery, and streamline remote collaboration for globally distributed editorial teams.

These integrations are available today to joint customers. Media organizations can explore deployment options that align with their existing infrastructure, security requirements, and growth plans.

Advancing Standards for Interoperability: Telestream Adopts EBU DMF Protocol

Telestream is pioneering one of the industry’s first workflow solutions developed for the Dynamic Media Facility (DMF) protocol, an EBU initiative redefining broadcast infrastructures beyond SMPTE 2110. Built on a fully software-defined, hardware-agnostic foundation, DMF promotes a cloud-native architecture with a unified Media Exchange Layer for faster-than-real-time processing, enhanced cybersecurity, and vendor-agnostic deployment. Telestream’s participation with EBU extends its interoperability strategy beyond vendor integrations to include open, standards-based approaches championed by leading European broadcasters and global partners.

As broadcasters prepare for the demands of their future infrastructure, Telestream’s DMF adoption underscores its commitment to delivering future-ready, standards-based workflows that maximize flexibility, reduce complexity, and enable true interoperability across the media supply chain.

See Telestream at IBC2025

Telestream will showcase these Vantage integrations at IBC2025, Stand 7.B21. To schedule a meeting or request a demonstration, visit https://www.telestream.net/ibc2025/#schedule-a-meeting-section.

About Telestream
Ingest. Enhance. Deliver.

Telestream has been at the forefront of digital media innovation for nearly three decades, serving as the trusted partner behind some of the world’s most mission-critical media operations. Its industry-leading test and measurement and media workflow solutions streamline operations and scale efficiently across the entire media lifecycle-from capture and live production to automation, processing, quality control, content management, and distribution. Designed for on-premises, cloud, and hybrid environments, Telestream ensures high-quality media delivery to any audience, on any platform. The company is privately held and headquartered in Nevada City, California. Learn more at www.telestream.net.

Press Contact

Kristin Canders
Grithaus Agency
(e) kristin@grithaus.agency
(p) +1 (207) 974-7744

SOURCE: Telestream LLC

View the original press release on ACCESS Newswire